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ABSTRACT
Background: Current standard neoadjuvant treatment 
for advanced ovarian cancer is 3-weekly platinum-based 
chemotherapy (CP3w). Patients unable to have interval 
debulking surgery (IDS) or with significant residual disease 
have a poor outcome to CP3w treatment. We investigated 
the outcome in patients who were switched to dose-dense 
chemotherapy.
Methods: We retrospectively analysed 30 patients treated 
at UCLH in 2009–2013, who switched to dose-dense 
chemotherapy after neoadjuvant CP3w, having achieved 
a poor response/progressed and unable to proceed to IDS 
(n=21), or had >1 cm residual disease after IDS (n=9). 
Treatment was 3-weekly carboplatin and weekly paclitaxel 
(n=23), or both drugs weekly (n=7). For comparison, we 
included 30 matched patients treated with CP3w followed 
by IDS (n=24, without or ≤1 cm residual disease; n=6, 
with >1 cm residual disease). Time to progression (TTP) 
and overall survival (OS) were measured from the date of 
diagnosis until progression (CT scan or CA-125) and death 
from any cause, respectively.
Results: Baseline characteristics were similar in both 
groups. The response rate to dose-dense chemotherapy 
was 70% (Gynecological Cancer Intergroup criteria). In the 
dose-dense group, 24 patients had tumour progression 
and 16 died; the corresponding numbers in the control 
group were 24 and 11. Median TTP was 15.8 months 
with dose-dense therapy, higher than expected for this 
patient group, and the same as in the control group (15.7 
months) undergoing IDS, p=0.27. Median TTP in patients 
with residual disease postsurgery was 16.5 months 
(dose-dense) and 10.8 months (controls), p=0.02. TTP in 
dose-dense patients who did not have surgery was 10.4 
months. Median OS was 31.3 (dose-dense) and 59.6 
months (controls), p=0.06. Dose-dense chemotherapy was 
well tolerated: only three patients interrupted treatment 
due to toxicity.
Conclusion: Switching to dose-dense chemotherapy 
in patients who failed to respond to CT3w neoadjuvant 
chemotherapy appears to be an effective strategy and 
requires further investigation.
INTRODUCTION
Ovarian cancer is the fifth most common cause 
of cancer death in women in most European 
countries.1 The standard treatment for 
patients with advanced (FIGO (International 
Federation of Gynecology and Obstetrics) 
stage IC–IV) disease is initial debulking 
surgery followed by 3-weekly carboplatin and 
paclitaxel combination chemotherapy.2 In 
patients undergoing surgery, this approach 
leads to median progression-free survival 
(PFS) ranging from 15 to 25 months and 
median overall survival (OS) from 24 to 40 
months. Patients with gross residual tumour 
after surgery tend to have lower PFS and their 
outcome is poor.3–7 The outcome of patients 
not amenable to surgery upfront but treated 
with neoadjuvant chemotherapy followed by 
surgery is similar.8 9
Despite improvements in chemotherapy, 
the tumour response in some patients is not 
sufficient to undergo surgery, or significant 
residual disease remains after surgery. The 
prognosis of these patients is very poor due 
to early progression.10–12 When this occurs, 
the aim of therapy changes from one of cura-
tive intent to palliation and management 
of a chronic disease, with the purpose of 
prolonging survival, maintaining or improving 
quality of life and good symptom control.
There is evidence from a Japanese 
randomised trial that delivering paclitaxel in a 
weekly ‘dose-dense’ schedule rather than every 
3 weeks in first-line treatment of advanced 
ovarian cancer increases the tumour response 
rate and prolongs survival.13 The mechanistic 
basis for these benefits is unclear but it has been 
postulated to involve Gompertzian models of 
chemotherapy regrowth and antiangiogenic 
mechanisms.14 15 Most commonly, weekly pacl-
itaxel (80 mg/m2) is given with six cycles of 
3-weekly carboplatin. This resulted in a 30% 
improvement in both PFS and OS compared 
with standard 3-weekly dose scheduling.13 16 In 
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a subsequent subgroup analysis, a similar clinical benefit of 
dose-dense chemotherapy was seen in patients with signifi-
cant residual disease after surgery.13 The treatment was well 
tolerated but there was a greater degree of haematological 
toxicity, leading to discontinuation of regimen in 60% of 
patients in the dose-dense arm compared with 43% in the 
standard arm.16 17
Given these findings, we postulated that patients whose 
tumours respond poorly or progress during a standard 
front-line chemotherapy given every 3 weeks, or who have 
residual disease after interval surgery, might benefit from 
a switch to a dose-dense scheduling of paclitaxel or both 
drugs. We explored this treatment policy in a group of 30 
women with advanced ovarian cancer treated at the UCL 
Hospitals, London.
PATIENTS AND METHODS
We reviewed the medical records of 30 consecutive 
patients treated at UCL Hospitals between 2009 and 2013 
who switched to dose-dense chemotherapy during first-
line 3-weekly chemotherapy for ovarian cancer. Patients 
switched mostly to weekly paclitaxel with 3-weekly carbo-
platin, but in some cases both drugs were given weekly. 
This change occurred after they were deemed to have 
had a poor initial response to chemotherapy and were 
unsuitable for interval debulking surgery (IDS), or after 
surgery if significant residual disease remained (>1 cm). 
We excluded patients who began chemotherapy on a 
dose-dense regimen.
In addition, we collected data on 30 patients treated 
during the same period who received standard 3-weekly 
neoadjuvant chemotherapy, IDS and then continued 
with 3-weekly postoperative chemotherapy. These were 
selected to have similar characteristics to those in the 
dose-dense group, for example, age, tumour type and 
stage at diagnosis. We chose this group as a comparator 
because they had responded to standard chemotherapy 
and underwent IDS for advanced ovarian cancer (the 
majority with no residual tumour after surgery), and 
hence were considered to be a group with better prog-
nosis and reflecting the standard practice population.
The study design is summarised in figure 1.
Demographic factors, treatment and response data 
(imaging and serum CA-125) were obtained from medical 
records.
Treatment
Standard 3-weekly chemotherapy was with carboplatin 
alone (C3w), or more commonly in combination with 
paclitaxel (CP3w). Carboplatin was administered at a dose 
of AUC 5 based on the Calvert formula18 using an EDTA 
glomerular filtration rate or AUC 6 based on a calculated 
creatinine clearance. Paclitaxel was administered at the 
dose of 175 mg/m2.
Dose-dense paclitaxel 80 mg/m2 was given continuously 
each week with 3-weekly carboplatin (CPw) in most cases 
but some patients received weekly paclitaxel with weekly 
carboplatin, given at an AUC 2 (CwPw)
Statistical methods
Data on response to chemotherapy were calculated using 
the Gynecological Cancer Intergroup response criteria,19 
using both serum CA-125 and radiological criteria. Radio-
logical data were obtained from reports in the case notes. 
For example, complete response (CR) was considered to 
be the disappearance of all known disease on CT scan 
and return of serum CA-125 levels to normal values 
(≤35 IU/mL) for at least 4 weeks. Partial response (PR) 
was considered to be a 30% decrease in the sum of the 
longest diameter of target lesions (evaluated by CT scan) 
in patients with measurable disease, or a 50% decrease 
in serum levels of CA-125 (confirmed with repeat serum 
CA-125 level after an interval of no less than 4 weeks). 
Progressive disease (PD) was considered to be appearance 
of new lesions, or more than 30% increase in the sum of 
the longest diameter of target lesions (evaluated by CT 
scan) in measurable disease or increase in serum levels 
of CA-125 more than twofold the nadir value in non-mea-
surable disease. All the remaining cases were considered 
stable disease (SD).
Key questions
What is already known about this subject?
 ► Current standard neoadjuvant treatment for advanced ovarian 
cancer is 3-weekly platinum-based chemotherapy followed by 
interval debulking surgery (IDS). However, the tumour response in 
some patients is not sufficient to undergo surgery or significant 
residual disease remains after surgery. The prognosis of these 
patients is very poor due to early progression. There is evidence that 
delivering paclitaxel in a weekly ‘dose-dense’ schedule rather than 
every 3 weeks in first-line treatment of advanced ovarian cancer 
increases the tumour response rate and prolongs survival.
What does this study add?
 ►  We retrospectively analysed 30 patients, treated in our Institution, 
who switched to dose-dense chemotherapy after neoadjuvant 
3-weekly platinum-based chemotherapy, having achieved a poor 
response/progressed and unable to proceed to IDS or had >1 cm 
residual disease after IDS. For comparison, we collected data 
on 30 patients who received standard 3-weekly neoadjuvant 
chemotherapy, IDS and then continued with 3-weekly postoperative 
chemotherapy.
 ► Although the dose-dense group had worse prognosis, we found 
similar median time to progression (TTP) in the two treatment 
groups, whereas median overall survival in the dose-dense group 
was longer than expected. In addition, patients in the dose group 
who had >1 cm residual disease after surgery showed significantly 
longer median TTP compared with  controls with residual after 
surgery.
How might this impact on clinical practice?
 ► This retrospective analysis suggests that effective disease 
control can be achieved in some patients despite an initial poor 
response to 3-weekly induction chemotherapy. Weekly dose-dense 
chemotherapy might improve the tumour response rate and in some 
cases it allows debulking surgery to be performed. Dose-dense 
treatment is therefore a policy that merits further exploration in 
patients responding poorly to 3-weekly chemotherapy for ovarian 
cancer.
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Figure 1 Consort-like flow chart of the study.
Haematological toxicities were graded according 
to Common Terminology Criteria for Adverse 
Events(CTCAE) of the National Cancer Institute and 
National Institutes of Health, version 4.0, May 2009. Data 
on non-haematologic toxicities were not consistently 
available, and so not collected.
Time to progression (TTP) was measured from the date 
of diagnosis until PD and OS was measured until death from 
any cause (all patients who died had recorded progression 
previously). Both were analysed using Kaplan-Meier curves 
and multivariable Cox regression modelling to compare 
the dose-dense group with controls, and allowing for base-
line factors such as age, tumour type, stage and CA-125.
RESULTS
Patients’ characteristics
Baseline characteristics are shown in table 1. Mean 
age at diagnosis was 67.5 years (range 28–83). Among 
dose-dense patients, all tumours were high-grade (G3) 
carcinoma and most had serous histology (n=26, 86.7%). 
A high proportion of patients had FIGO stage IV disease 
(14 patients, 46.7%); the rest had stage 3C (16 patients, 
53.3%). In seven patients CA-125 data were not available.
Initial treatment and surgery
Details of treatment are provided in table 1. In the dose-
dense group, most patients were treated initially with 
the combination of carboplatin and paclitaxel (CP3w) 
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Table 1 Baseline characteristics and treatment details (number of patients with percentages in brackets, except for age, CA-





Age at diagnosis, years
 Median (range) 67.5 (28–83) 68.5 (37–81) 0.72
Tumour type
 Ovarian 22 (73.3) 17 (56.7) 0.28
 PPC/fallopian tube 8 (26.7) 13 (43.3)
Histology
 Serous 26 (86.7) 29 (96.7) 0.48
 Endometrioid 1 (3.3) 1 (3.3)
 Mucinous 1 (3.3) 0
 Undifferentiated 2 (6.7) 0
Grade
 Grade 3 30 (100) 30 (100)
Stage (FIGO)
 IIIC 16 (53.3) 15 (50) 0.99
 IV 14 (46.7) 15 (50)
CA-125 at diagnosis, 
units/mL
 Median (range) 1287 (119–9937)† 950 (87–9000) 0.29
Initial treatment type
 CP3w 21 (70) 22 (73.3) 0.99
 C3w 9 (30) 8 (26.7) 0.88
 Median no of cycles 
(range)
3 (1–6) 3 (3–4)
Reason for switching 
to dose-dense 
chemotherapy
 Progression 2 (6.7)
 Poor response 19 (63.3)
 Residual after surgery 9 (30)
Dose-dense 
chemotherapy type
 CPw 23 (76.7)
 CwPw 7 (23.3)




 Yes 12 (40) 30 (100)







Residual disease after 
surgery
 ≤1 cm 2 (6.7) 24 (80)
 >1 cm 10 (66.7) 6 (20) <0.001
No of further lines of 
chemotherapy, median 
(range)
1 (1–4) 2 (1–4) 0.40
*Wilcoxon two-sample test for age, CA-125 and number of cycles; Fisher's exact test for all others
†For 23 patients who had CA-125 measurements
CP3w, carboplatin and paclitaxel 3-weekly; C3w, carboplatin 3-weekly; CPw, carboplatin 3-weekly and paclitaxel weekly; CwPw, 
carboplatin and paclitaxel weekly; PPC, Primary Peritoneal Cancer.
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(n=21, 70%) but nine patients (30%) received single 
agent carboplatin (C3w). Most patients switched to dose-
dense therapy after three (n=23, 76.7%) or four cycles 
(n=4, 13.3%) of chemotherapy. In one patient, the switch 
was made after the first cycle of standard therapy due to 
tumour progression, and two patients received a total 
of six cycles before switching. All patients were assessed 
for response at the end of initial three to four cycles of 
chemotherapy.
Twenty-one patients (70%) had a poor response to initial 
treatment and were considered unsuitable for IDS and 
because of this switched to dose-dense chemotherapy; of 
these, two patients switched because of tumour progression 
during the first three to four cycles of chemotherapy.
Nine patients (30%) switched to dose-dense chemo-
therapy after surgery, due to significant residual disease.
Three patients in the dose-dense group underwent 
surgery after the completion of the dose-dense chemo-
therapy, having initially been considered unsuitable for 
surgery. Optimal debulking with no residual disease was 
achieved in two, whereas the other still had significant 
residual disease after surgery. Therefore, a total of 12 
(40%) dose-dense patients underwent debulking surgery.
In the control group, the majority of patients (n=22, 
73.3%) were treated with carboplatin AUC 5–6 and pacl-
itaxel 175 mg/m2 (CP3w); eight patients (26.7%) were 
treated with the same dose of single agent carboplatin. 
All patients underwent IDS after a PR to neoadjuvant 
chemotherapy. In 80% of patients (n=24) this resulted 
in optimal debulking with ≤1 cm of residual; six patients 
(20%) had >1 cm residual disease after surgery. Patients 
received a median of 3 (range 2–3) cycles of postoperative 
chemotherapy. Two patients in this group received beva-
cizumab which was continued as maintenance therapy for 
up to 1 year.
Dose-dense treatment
The majority of patients in the dose-dense group switched 
to CPw (n=23, 76.7%); seven patients switched to CwPw. 
Most of patients received three cycles of dose-dense 
chemotherapy (n=19, 63.3%), five patients received less 
than one to two cycles (16.6%) and six patients (20%) 
received up to six cycles. Response was assessed at the 
end of the dose-dense chemotherapy. Six patients were 
not assessable for response. Out of the 24 evaluable 
patients, 5 patients (20.8%) achieved a  CR, 13 patients 
(54.2%) a PR, 3 (12.5%) had SD, and 3 (12.5%) had 
disease progression during the chemotherapy. Addition-
ally, four patients received bevacizumab as part of their 
dose-dense treatment and as maintenance therapy for up 
to 1 year of administration.
Survival analysis
The median follow-up was 42 months among all patients 
(censoring those who were alive); 37 and 42 months in 
the dose-dense control groups, respectively. This slightly 
longer follow-up might contribute towards a difference in 
survival times in favour of controls, however the median 
follow-up among patients who were still alive was similar, 
37 and 38 months.
The median TTP was similar between patients in the 
dose-dense group and controls: 15.8 and 15.7 months 
(table 2 and figure 2), p=0.38. The OS in the dose-dense 
group was 31.3 months, lower than in controls, 59.6 
months (p=0.06).
The effect of several clinical factors (such as debulking 
surgery or not, residual disease after surgery, type of 
initial chemotherapy and number of cycles of initial 
chemotherapy) on TTP and OS are shown in table 2 and 
figures 3–4. TTP was significantly higher among the dose-
dense group who had >1 cm residual disease after surgery 
(16.5 months), compared with controls with residual 
after surgery (10.8 months), p=0.005. There were no 
other clear differences in TTP or OS between dose-dense 
patients and controls, according to the factors examined 
(table 2, figures 3–4).
In the dose-dense group, patients who had surgery 
had a longer TTP than those who did not have surgery: 
17.0 vs 10.4 months (p=0.09, unadjusted HR 0.46, 95% CI 
0.19 to 1.12; and adjusted HR 0.34, 95% CI 0.07 to 1.59). 
The difference was greater for OS: 43.2 vs 21.1 months 
(p=0.046, unadjusted HR 0.31, 95% CI 0.10 to 0.98; 
and adjusted HR 0.18, 95% CI 0.02 to 1.26). There was 
also some evidence that the median OS was higher for 
patients who initially had CP3w versus C3w (43.2 vs 22.7 
months), unadjusted HR=0.25, 95% CI 0.08 to 0.72, 
p=0.01; adjusted HR=0.29, 95% CI 0.05 to 1.78, p=0.18. 
Patients who had CPw as dose-dense therapy had higher 
median OS than CwPw (43.2 vs 21.1 months); unadjusted 
HR 0.48, 95% CI 0.17 to 1.32, p=0.15; adjusted HR 0.16, 
95% CI 0.03 to 0.90, p=0.04 (including also type of initial 
chemotherapy).
Toxicity of dose-dense therapy
Detailed data on haematological toxicities are reported in 
table 3. Grade 3 or 4 neutropenia was the most common 
treatment-related adverse event, seen in 50% of patients. 
No cases of febrile neutropenia were observed. Grade 2 
anaemia was seen in 36.7% of patients. Interestingly, only 
three patients interrupted treatment due to toxicity. In 
most cases, toxicities were easily managed with treatment 
delays (n=13, 43.3%) or dose reductions (n=17, 56.7%).
DISCUSSION
We instituted a change of treatment schedule policy 
starting dose-dense therapy in patients who responded 
poorly to neoadjuvant chemotherapy who were not able to 
undergo IDS or who had a poor surgical result from IDS. 
These patients have short median TTP, and a very poor 
prognosis, with a median OS usually not exceeding 16 
months.3 4 7 10 Similar findings are observed in patients who 
do not have optimal debulking at IDS, but most continue 
on the same regimen of chemotherapy postoperatively.20 21 
There are no clear guidelines about how best to manage 
this group of women who have a poor prognosis, and we 
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n=30 Unadjusted HR (95% CI) Adjusted HR (95% CI)*
Median, months (95% CI)
All patients
TTP 15.8 (10.4 to 17.3) 15.7 (11.7 to 21.8) 1.29 (0.73 to 2.29) 1.67 (0.84 to 3.34),
Events (n) 24 24 p=0.38 p=0.14
OS 31.3 (19.7 to ne) 59.6 (34.0 to ne) 2.08 (0.94 to 4.62) 2.35 (0.96 to 5.74)
Events (n) 16 11 p=0.06 p=0.06
Debulking surgery
 Yes TTP 17.0 (11.3 to 29.3) 15.7 (11.7 to 21.8) 0.84 (0.38 to 1.89) 1.03 (0.36 to 2.95)
OS 43.2 (24.0 to ne) 1.08 (0.33 to 3.53) 1.73 (0.36 to 8.38)
 No TTP 10.4 (8.5 to 17.3) -
OS 21.1 (10.8 to 31.3) -
Residual disease
 ≤1 cm TTP Only 2 patients 18.0 (13.7 to 24.4)
OS 59.6 (28.8 to ne)
 >1 cm TTP 16.5 (11.3 to 29.3) 10.8 (4.5 to 14.0) 0.10 (0.02 to 0.49) 0.02 (<0.01 to 0.34)
OS 43.2 (24.0 to ne) Not reached 1.15 (0.21 to 6.31) 1.50 (0.09 to 24.1)
Type of initial chemotherapy
 CP3w TTP 16.1 (10.3 to 18.6) 14.6 (10.1 to 18.5) 0.95 (0.48 to 1.87) 1.08 (0.45 to 2.57)
OS 43.2 (21.1 to ne) Not reached 1.35 (0.47 to 3.89) 1.75 (0.54 to 5.67)
 C3w TTP 15.0 (4.0 to 24.2) 23.1 (5.8, ne) 3.12 (0.91 to 10.70) 6.87 (0.82 to 57.6)
OS 22.7 (5.1 to 30.6) 53.7 (12.1 to 59.6) 7.11 (1.43 to 35.4) 4.21 (0.45 to 39.3)
Cycles of initial chemotherapy (n)
 ≤3 TTP 15.8 (10.4 to 22.0) 15.6 (10.8 to 21.8) 1.10 (0.59 to 2.06) 1.69 (0.79 to 3.65)
OS 30.6 (17.2 to ne) 47.8 (34.0 to ne) 1.88 (0.80 to 4.42) 1.98 (0.74 to 5.31)
 ≥4 TTP 15.9 (8.5 to 18.6) 15.9 (13.7 to ne) (only 11 patients)
OS 34.7 (9.9 to ne) Not reached
Type of dose-dense chemotherapy





 ≤3 TTP 15.8 (10.4 to 17.3)
OS 21.1 (19.7 to ne)
 ≥4 TTP 15.9 (6.6 to 24.2)
OS 21.1 (13.9 to 34.7)
*Allowing for age, tumour type, stage and CA-125
CP3w, carboplatin and paclitaxel 3-weekly; C3w, carboplatin 3-weekly; CPw, carboplatin 3-weekly and paclitaxel weekly; CwPw, 
carboplatin and paclitaxel weekly; OS, overall survival; ne, not estimable; TTP, time to progression.
hypothesised that in this group dose-dense chemotherapy 
may reduce resistance to chemotherapy.
In this retrospective analysis, we showed that switching 
to a weekly schedule is feasible and might benefit patients 
in this poor prognosis group. On switching to dose-dense 
chemotherapy after a poor response to 3-weekly induc-
tion chemotherapy, or suboptimal surgery, the overall 
CR rate at the end of weekly treatment was 20.8%, and 
54.2% of patients had a partial tumour response. The 
median TTP and OS were 15.8 and 31.3 months, respec-
tively, longer than expected from previously published 
reports in this population, where they typically are about 
10 and 16 months, respectively.3 4 7 10 Only three patients 
developed tumour progression during weekly treatment. 
Haematological toxicity was acceptable, consistent with 
previous reports that show CPw and CwPw are tolerable 
in most women.13 22 23
The median TTP in the dose-dense group with residual 
disease after attempted IDS was significantly higher than 
the corresponding control patients treated with standard 
3-weekly chemotherapy (16.5 vs 10.8 months, respectively; 
p=0.005). The median number of ‘post switch’ chemo-
therapy cycles was three, but the extended duration of 
treatment in a few patients may have contributed to a 
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Figure 2 Time to progression (upper) and overall survival (lower) for patients switched to dose-dense chemotherapy and 
controls.
longer TTP in this group. OS is dependent on stage and 
histology and the completeness of surgical debulking and 
a median OS of 31.3 months in these patients is encour-
aging. For example, in previously published randomised 
trials of initial surgery with complete resection of disease 
followed by chemotherapy the median survival was 99.1 
months.7 Whereas, patients entered into a neoadjuvant 
versus primary surgery trial, the survival of women under-
going complete surgical debulking ranged from a median 
of 38 months in the IDS group to 45 months in the same 
population who had primary surgery.8 The median OS 
in the dose-dense group also compares favourably with 
the median survival of 59.6 months seen in the case–
control group where 80% of the patients had no residual 
disease following IDS. It is similar to the median OS of 
25–26 months reported by Vergote et al8 in patients with 
macroscopic residual disease (>1 cm) irrespective of the 
timing of surgery. In our previously reported case series 
of patients receiving 3-weekly chemotherapy, the median 
OS was 22.5 months in patients undergoing suboptimal 
surgery and 7.8 months in those who never had surgery.24 
However, our findings are based on a single-centre study 
and the results were compared with a non-randomised 
matched control group who responded to neoadjuvant 
chemotherapy. Both factors may confound or bias the 
results we have reported. However, within patients, we 
observed a change in response in some patients when 
switched to a dose-dense schedule and recommend that 
further prospective studies are performed.
The strategy of switching the scheduling of chemo-
therapy in poorly responding patients has been explored 
by others25 but there have been no randomised trials 
comparing a switch to a dose-dense strategy with continu-
ation of the same treatment regimen. We used a historical 
case–control series from our institution to help put our 
findings into the context of our standard practice. There 
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Figure 3 Time to progression and overall survival for patients according to four factors (in order, top to bottom): debulking 
surgery or not, residual disease after surgery, type of initial chemotherapy and number of cycles of initial chemotherapy. CP3w, 
carboplatin and paclitaxel 3-weekly; C3w, carboplatin 3-weekly.
is no clear guidance about how best to manage patients 
who have significant tumour residuum after IDS or those 
unable to proceed to surgery after three to four cycles of 
neoadjuvant chemotherapy. Standard practice is gener-
ally to continue with 3-weekly treatment. Some would 
advocate adding bevacizumab, extrapolating the evidence 
reported in the ICON7 trial that bevacizumab is more 
effective in patients with bulky residual disease or in those 
who have not undergone surgery.26 Following the results 
of the Japanese dose-dense paclitaxel trial (JGOG 3016), 
some clinicians now use a dose-dense regimen for patients 
with newly diagnosed advanced OC, including those who 
are appropriate for IDS. However, this approach should 
not be considered a standard regimen until more reliable 
evidence is obtained.
Our retrospective analysis suggests that effective 
disease control can be achieved in some patients despite 
an initial poor response to 3-weekly induction chemo-
therapy. Weekly dose-dense chemotherapy might improve 
the tumour response rate and in some cases it allows 
debulking surgery to be performed. Dose-dense treat-
ment is therefore a policy that merits further exploration 
in patients responding poorly to 3-weekly chemotherapy 
for ovarian cancer.
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Figure 4 Time to progression and overall survival for patients who had dose-dense chemotherapy, according to two factors 
(in order, top to bottom): type of dose-dense chemotherapy and number of cycles of dose-dense chemotherapy. CPw, 
carboplatin 3-weekly and paclitaxel weekly; CwPw, carboplatin and paclitaxel weekly.
Table 3 Toxicities of dose-dense treatment


































Treatment interrupted for toxicity 3 (10)
Delays for toxicities 13 (43.3)
Required dose reductions 17 (56.7)
Because of rounding off, the sum of percentages does not always 
equal 100.
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